AMP Molecule Fights Sepsis Muscle Loss by Targeting AMPK and Inflammation
Adenosine 5'-monophosphate preserves muscle mass during sepsis by activating AMPK and blocking IL-1β, offering a potential new therapy.
Summary
Sepsis commonly destroys muscle tissue, causing lasting weakness even after patients recover. Researchers at Juntendo University tested whether adenosine 5'-monophosphate (AMP) — a naturally occurring molecule — could prevent this muscle loss. Using a mouse sepsis model, cell cultures, and human patient samples, they found that AMP activated the metabolic enzyme AMPK while suppressing the inflammatory cytokine IL-1β. Treated mice showed better grip strength and preserved muscle mass. In cell studies, AMP reduced LPS-triggered inflammation in macrophages and prevented muscle fiber shrinkage. Human sepsis patients with muscle wasting had elevated inflammatory markers consistent with the proposed mechanism. These findings suggest AMP could be a novel therapeutic approach to protecting skeletal muscle in critically ill patients.
Detailed Summary
Sepsis-associated muscle wasting (SAMW) is a devastating complication of severe infection that causes long-term physical disability and reduced quality of life, even after the acute illness resolves. No effective pharmacological treatment currently exists to prevent this muscle deterioration, making new therapeutic strategies urgently needed.
Researchers at Juntendo University investigated whether adenosine 5'-monophosphate (AMP), a naturally occurring nucleotide with known organ-protective properties, could mitigate SAMW. Using a well-established mouse model of sepsis — cecal ligation and puncture — male mice received intraperitoneal AMP or saline. Complementary cell culture experiments used C2C12 myoblasts and RAW264.7 macrophages exposed to LPS and IL-1β. Human plasma samples from sepsis patients were also analyzed to assess translational relevance.
AMP treatment suppressed sepsis-driven inflammatory cytokine production, particularly IL-1β, while activating AMPK signaling and attenuating mTORC1 activation — a pathway implicated in muscle protein breakdown. Treated mice demonstrated improved forelimb grip strength and better-preserved muscle mass. In cell cultures, AMP reduced macrophage IL-1β output and protected myotubes from atrophy, also shifting muscle fiber characteristics toward a fast-twitch phenotype. Clinical samples confirmed that elevated inflammatory cytokines correlate with muscle wasting in sepsis patients.
These findings position AMP as a dual-action therapeutic candidate: dampening systemic inflammation while simultaneously promoting muscle-preserving metabolic signaling. Given AMPK's central role in cellular energy homeostasis and its known anti-inflammatory effects, AMP's mechanism is biologically plausible and builds on existing research into metabolic regulators.
Important caveats apply. The primary model is animal-based, and translating mouse sepsis findings to human critical care has historically proven difficult. The study is also limited to male mice, leaving sex-based differences unexplored. Additionally, this summary is based on the abstract only, as the full text is not open access.
Key Findings
- AMP activated AMPK signaling and suppressed IL-1β, preserving muscle mass in septic mice.
- AMP-treated mice showed measurably improved forelimb grip strength compared to controls.
- AMP reduced LPS-induced IL-1β production in macrophages and protected myotubes from atrophy in vitro.
- Human sepsis patients with muscle wasting had elevated inflammatory cytokines consistent with the proposed mechanism.
- AMP shifted muscle fibers toward a fast-twitch phenotype, suggesting functional as well as structural benefits.
Methodology
The study used a mouse cecal ligation and puncture sepsis model with male C57BL/6 mice receiving intraperitoneal AMP or saline. In vitro experiments employed C2C12 myoblast and RAW264.7 macrophage cell lines treated with LPS and IL-1β. Human sepsis patient plasma was analyzed for inflammatory cytokine levels to support translational relevance.
Study Limitations
The study used only male mice, so sex-based differences in AMP response remain unknown and should be addressed in future work. Translation from murine sepsis models to human critical illness has a poor historical track record, requiring validation in human trials. This summary is based on the abstract only, as the full paper is not open access, limiting assessment of methodological detail.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: